<DOC>
	<DOC>NCT00413036</DOC>
	<brief_summary>Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop</brief_summary>
	<brief_title>A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Key Inclusion criteria Biopsy proven aggressive nonhodgkin's lymphoma Follicular center lymphoma Grade 3. Diffuse large Bcell lymphoma. Mantle cell lymphoma. Transformed lymphoma. Relapsed or refractory to previous therapy for lymphoma At least one prior combination chemotherapy regime Measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2 Willing to follow the pregnancy precautions Key Exclusion criteria Any of the following laboratory abnormalities. Absolute neutrophil count (ANC) &lt; 1,500 cells/mm^3 (1.5*10^9/L). Platelet count &lt; 60,000/mm^3 (60*10^9/L). Calculated creatinine clearance of &lt;50mL/min Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) or Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times upper limit of normal (ULN). Serum total bilirubin &gt; 2.0 mg/dL (34 Âµmol/L)/conjugated bilirubin &gt;0.8mg/dL. Subjects who are candidates for and willing to undergo an autologous stem cell transplant. History of active Central Nervous System (CNS) lymphoma within the previous 6 months History of other malignancies within the past year Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Celgene</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Non-hodgkin's lymphoma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC5013</keyword>
	<keyword>NHL</keyword>
</DOC>